O
JAZZ icon

OrbiMed’s Jazz Pharmaceuticals JAZZ Stock Holding History

OrbiMed’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-884,000
Closed -$149M – 141
2018
Q3 		$149M Sell
884,000
-156,100
-15% -$26.8M 1.79% 15
2018
Q2 		$179M Hold
1,040,100
– – 2.14% 10
2018
Q1 		$157M Buy
1,040,100
+432,200
+71% +$63.4M 1.95% 13
2017
Q4 		$81.9M Sell
607,900
-141,300
-19% -$19.6M 1.04% 30
2017
Q3 		$110M Buy
749,200
+203,300
+37% +$30.7M 1.05% 31
2017
Q2 		$84.9M Buy
545,900
+174,500
+47% +$26.7M 0.89% 37
2017
Q1 		$53.9M Hold
371,400
– – 0.61% 51
2016
Q4 		$40.5M Buy
371,400
+124,500
+50% +$13.9M 0.52% 53
2016
Q3 		$30M Buy
246,900
+156,900
+174% +$21.1M 0.34% 64
2016
Q2 		$12.7M Hold
90,000
– – 0.13% 88
2016
Q1 		$11.8M Hold
90,000
– – 0.12% 85
2015
Q4 		$12.7M Sell
90,000
-25,000
-22% -$3.46M 0.11% 85
2015
Q3 		$15.3M Hold
115,000
– – 0.15% 79
2015
Q2 		$20.2M Hold
115,000
– – 0.17% 83
2015
Q1 		$19.9M Hold
115,000
– – 0.17% 80
2014
Q4 		$18.8M Hold
115,000
– – 0.18% 79
2014
Q3 		$18.5M Hold
115,000
– – 0.19% 78
2014
Q2 		$16.9M Hold
115,000
– – 0.2% 69
2014
Q1 		$15.9M Hold
115,000
– – 0.2% 71
2013
Q4 		$14.6M Buy
115,000
+43,000
+60% +$4.45M 0.21% 71
2013
Q3 		$6.62M Hold
72,000
– – 0.12% 92
2013
Q2 		$4.95M Buy
+72,000
New +$4.4M 0.1% 99

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's JAZZ Position: Q4 2018 in Review

OrbiMed sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 884,000 shares — an estimated $149M sold.

OrbiMed first reported a position in JAZZ in Q2 2013 and held it in 22 quarters. The position peaked at $179M in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • OrbiMed reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • OrbiMed sold 884,000 Jazz Pharmaceuticals shares in Q4 2018, an estimated $149M.
  • OrbiMed first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • OrbiMed's Jazz Pharmaceuticals position peaked at $179M in Q2 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.